Xencor, Inc. (XNCR)

Revenue by Segment

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016
Discovering and Developing Engineered Antibody Therapeutics	125.58M	110.49M	174.62M	164.58M	275.11M
Discovering and Developing Engineered Antibody Therapeutics Growth	13.65%	-36.72%	6.10%	-40.18%	124.23%
Total	125.58M	110.49M	174.62M	164.58M	275.11M
Total Growth	13.65%	-36.72%	6.10%	-40.18%	124.23%

Data Source: S&P Global Market Intelligence Last updated: May 6, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Jun 21, 2026

Data Sources Report a data error